New drug duo aims to slow rare spleen cancer
NCT ID NCT05735834
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to two years, with follow-up for three years. The main goal is to see if the combination keeps the cancer from growing longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENIC MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O.U. Policlinico G. Rodolico-S. Marco
Catania, 95123, Italy
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
ASST Spedali Civili di Brescia
Brescia, 25123, Italy
-
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Palermo, 90146, Italy
-
Azienda Ospedaliero Universitaria Maggiore della Carità
Novara, 28100, Italy
-
CHRU Nancy Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHU de Grenoble
Grenoble, 38043, France
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Clatterbridge Cancer Centre
Liverpool, L7 8YA, United Kingdom
-
Clinica Universidad de Navarra
Madrid, Spain
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Guy's Hospital - Guy's and St. Thomas' NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Hospedal Clinic de Barcelona
Barcelona, Spain
-
Hospital 12 De Octubre
Madrid, Spain
-
Hospital Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Hospital Clinico De Valencia
Valencia, Spain
-
Hospital De Donostia
San Sebastián, Spain
-
Hospital De Salamanca
Salamanca, Spain
-
Hospital Gregorio Marañón
Madrid, Spain
-
Hospital Ramon y Cajal
Madrid, Spain
-
Hospital Universitario Cruces
Bilbao, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, Spain
-
Hospital Vall d'Hebron
Barcelona, Spain
-
Hospital Virgen Arrixaca
El Palmar, Spain
-
Hospital del Mar
Barcelona, Spain
-
Hôpital Lyon-Sud
Pierre-Bénite, 69495, France
-
Hôpital Saint Louis
Paris, 75475, France
-
INSELSPITAL, Bern University Hospital
Bern, 3010, Switzerland
-
IRCCS AOU di Bologna
Bologna, 40138, Italy
-
IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, 47014, Italy
-
IRCCS Istituto Tumori Giovanni Paolo II
Bari, 70124, Italy
-
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
-
IRCCS Policlinico San Matteo
Pavia, Italy
-
Institut Bergonié
Bordeaux, 33076, France
-
Istitut Català d'Oncologia, Hospital Duran i Reynals
Barcelona, Spain
-
Karolinska University Hospital
Stockholm, Sweden
-
Medical University of Vienna
Vienna, Austria
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
-
Oslo University Hospital
Oslo, Norway
-
Ospedale Santa Maria delle Croci
Ravenna, 48121, Italy
-
Ospedale di Circolo e Fondazione Macchi - ASST dei Sette Laghi
Varese, 21100, Italy
-
Policlinico Santa Maria alle Scotte
Siena, 53100, Italy
-
The Christie
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
-
USL-IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova
Reggio Emilia, 42123, Italy
-
University College London Hospitals
London, NW1 2PG, United Kingdom
-
University Hospital of Wales
Cardiff, CF14 4XW, United Kingdom
-
University Hospitals Dorset
Bournemouth, BH7 7DW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 3D-Printed models unlock personalized blood cancer therapies?
- New drug duo targets hard-to-treat lymphoma
- New Two-Step transplant shows promise for blood cancer patients
- New combo shows promise for tough lymphomas
- New strategy aims to tame common virus after stem cell transplants
- Engineered immune cells take aim at Hard-to-Treat blood cancers